Neuronetics Q2 2026 Earnings: A Modest Step Toward Profitability for STIM, With a TMS-Touched Path Forward

Ticker: STIM. In this quarter, the company’s EPS narrative was not driven by a blockbuster beat but by a measured move toward profitability. Investors will be watching EPS consensus and any earnings surprise as the company bridges top-line progress with a still-narrow path to GAAP profitability. Revenue forecast dynamics for the next quarter will matter as management leans on a growing Greenbrook network and its NeuroStar platform.

What Neuronetics reported for the quarter ended June 30, 2026

Neuronetics, Inc. (NASDAQ: STIM) reported total revenue of $41.6 million in the quarter, up 9.1% from the prior year. Greenbrook revenue contributed $26.9 million, a 16.8% year-over-year increase. On the profitability line, the company posted Adjusted EBITDA of $0.3 million, reversing a $5.6 million loss in the second quarter of 2025. Net loss stood at $3.4 million, versus $10.1 million a year ago. On the cash front, net cash used in operations and investing was $1.4 million, a meaningful improvement from $3.8 million in the prior-year period.

Management framed these results as tangible progress toward sustained profitability and positive net cash flow from operations and investing, underscoring the value of combining NeuroStar TMS with the Greenbrook clinic network. The press release does not publish GAAP earnings per share (EPS) for the quarter, so the EPS figure the market will care about remains a function of future reporting and any potential adjustments during reconciliation. The absence of a stated EPS in the release opens the door for an earnings surprise risk in forthcoming disclosures, as analysts translate revenue growth and EBITDA into a bottom-line figure.

Operational highlights and leadership moves

Beyond the headline numbers, Neuronetics announced notable leadership changes aimed at sharpening financial discipline and commercial execution. Nir Naor was appointed Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer. Cory Anderson was promoted to Executive Vice President/General Manager of the Greenbrook clinics, and Rob Greene was named Senior Vice President of Sales. CEO Dan Reuvers described the quarter as evidence of “real operational progress,” emphasizing broader customer access to NeuroStar within a national care network as a driver of future profitability.

These moves suggest a deliberate strategy to convert top-line gains into more durable cash flow and to align leadership incentives with scale, cross-sell opportunities, and cost discipline. If the ESG of this plan holds up—tightening cost lines, improving utilization, and leveraging the Greenbrook footprint—the earnings surprise risk could tilt toward positive, especially if the market buffers on EBITDA improvements translating into a cleaner EPS path over time.

Numbers in context: Revenues by segment and cash dynamics

In a focused look at the quarterly table, total revenues by segment show a healthy mix: the Greenbrook network delivered approximately two-thirds of group revenue, maintaining its growth trajectory, while the NeuroStar platform continues to expand its market penetration. The company’s cash burn moderated meaningfully, with net cash used in operations and investing of about $1.4 million—an improvement versus $3.8 million in the second quarter of 2025. This cadence matters because, in a specialty medical technology company with a growth-oriented cost base, a sustained reduction in cash burn is often the more reliable signal of operating leverage than a headline EBITDA number.

What this could portend for Neuronetics’ peers and the sector

The results sketch a familiar arc for niche medical technology players: a platform (NeuroStar) coexists with a network (Greenbrook), enabling incremental revenue per patient and better access through integrated care. If management sustains the operating leverage implied by the quarter—higher revenue, steady or improved gross margins, and a cleaner cash burn profile—the company could begin to demonstrate a more durable EPS trajectory, even if near-term GAAP EPS remains negative. For sector peers in neuromodulation and outpatient care networks, the lesson is to watch not only top-line growth but how quickly a company can translate that growth into cash flow and, eventually, earnings per share that align with consensus expectations.

Analysts will be comparing this quarter to a relatively weak prior-year comparator, which can flatter sequential progress. As such, the earnings surprise risk will hinge on how aggressively cost initiatives, payer mix optimization, and utilization gains translate into a cleaner earnings metric and a supportive revenue forecast for the next quarter and beyond. In a space where clinical adoption, reimbursement dynamics, and clinic network expansion interact, the pace of profitability remains the real cliffhanger—and the stock price will likely respond to quarterly EPS narratives just as much as to revenue growth data.

What to watch next

EPS and EPS consensus updates in the forthcoming quarterly results; keep an eye on any GAAP EPS vs. Adjusted EBITDA reconciliation to gauge earnings surprises.
Revenue forecast revisions as payer coverage expands and patient access scales across the Greenbrook network.
Progress toward positive net cash flow from operations and investing, and any changes in capital requirements or working capital dynamics.
Management commentary on path to profitability, including potential capital needs or strategic partnerships that could alter the margin profile.